The NSAID roller coaster: More about rofecoxib

British Journal of Clinical Pharmacology

Volumn 62, Issue 3, 2006, Pages 257-259

  Aronson, J K ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZAPROPAZONE; CELECOXIB; CIMICOXIB; CLOZAPINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 1A2; DERACOXIB; ETORICOXIB; FIROCOXIB; IBUPROFEN; INDOMETACIN; LIDOCAINE; LUMIRACOXIB; MAVACOXIB; MELATONIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PARACETAMOL; PARECOXIB; RILUZOLE; ROBENACOXIB; ROFECOXIB; ROPIVACAINE; TACRINE; TILMACOXIB; TIZANIDINE; UNCLASSIFIED DRUG; VALDECOXIB; ZOLMITRIPTAN;

CARDIOVASCULAR DISEASE; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SELECTIVITY; EDITORIAL; GASTROSCOPY; HUMAN; NEPHROTOXICITY; PRESCRIPTION; PRIORITY JOURNAL; SKIN TOXICITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DRUG APPROVAL; HUMANS; LACTONES; SULFONES;

EID: 33747033209     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02761.x     Document Type: Editorial

References (25)

1. Flower RJ. Prostaglandins, bioassay and inflammation. Br J Pharmacol 2006; 147 Suppl 1 : S182-92.
2. Douthwaite A, Lintott CA. Gastroscopic observations of the effect of aspirin and certain other substances on the stomach. Lancet 1938; 2: 1222-5.
3. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, Murphy M, Vessey MP, Colin-Jones DG. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8.
4. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972; 240: 410-1.
5. Botting RM, Botting JH. The discovery of COX-2. In: Pairet M, van Ryn J (editors). COX-2 Inhibitors. Basel, Boston, Berlin: Birkhäuser Verlag, 2004: 1-13.
6. Berenbaum F. COX-3: fact or fancy? Joint Bone Spine 2004; 71: 451-3.
7. Hayllar J, Bjarnason I. NSAIDs, Cox-2 inhibitors, and the gut. Lancet 1995; 346: 521-2.
8. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14.
9. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, Subbaramaiah K, Dannenberg AJ. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001; 7: 3971-6.
10. Moncada S. Obituary: John R. Vane (1927-2004). Nature 2005; 433: 28.
11. McCartney SA, Mitchell JA, Fairclough PD, Farthing MJ, Warner TD. Selective COX-2 inhibitors and human inflammatory bowel disease. Aliment Pharmacol Ther 1999; 13: 1115-7.
12. Garcia B, Ramaholimihaso F, Diebold MD, Cadiot G, Thiefin G. Ischaemic colitis in a patient taking meloxicam. Lancet 2001; 357: 690.
13. Freitas J, Farricha V, Nascimento I, Borralho P, Parames A. Rofecoxib: a possible cause of acute colitis. J Clin Gastroenterol 2002; 34: 451-3.
14. Backman JT, Karjalainen MJ, Neuvonen M, Laitila J, Neuvonen PJ. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in health subjects. Br J Clin Pharmacol 2006; 61: 345-57.
15. Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ 2004; 171: 1027-8.
16. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-102.
17. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
18. Gibson L. Spanish drug editor wins case brought by Merck, Sharp Dohme. BMJ 2004; 328: 307.
19. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91.
20. European Medicines Agency concludes action on COX-2 inhibitors. http://www.emea.eu.int/pdfs/human/press/pr/20776605en.pdf (last accessed 2 August 2006).
21. Williams D, Singh M, Hind C. The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. Br J Clin Pharmacol 2006; 61: 366-8.
22. Knights KM, Mangoni AA, Miners JO. Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime? Br J Clin Pharmacol 2006; 61: 738-40.
23. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327: 1222-5.
24. McGettigan P, Han P, Henry D. Cyclooxygenase-2 inhibitors and coronary occlusion - exploring dose-response relationships. Br J Clin Pharmacol 2006; 61: 358-65.
25. Levesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 2006; 174: 1563-9.